Genetically engineered vaccinia viruses
AssigneesNational University Corporation Tottori University, Astellas Pharma Inc.
InventorsTakafumi Nakamura, Hajime Kurosaki, Motomu Nakatake
Life of this patent
Estimating the term…
Abstract
The present invention provides a genetically recombinant vaccinia virus effective in preventing or treating cancer. Specifically, the present invention provides a recombinant vaccinia virus lacking functions of VGF and O1L and having a gene encoding B5R in which an SCR domain has been deleted. Specifically, the present invention provides a vaccinia virus comprising two polynucleotides, a polynucleotide encoding IL-7 and a polynucleotide encoding IL-12; a combination kit of two vaccinia viruses, a vaccinia virus comprising a polynucleotide encoding IL-7 and a vaccinia virus comprising a polynucleotide encoding IL-12; and use of the two vaccinia viruses in combination.
Claims8
A method of treating cancer comprising administering intratumorally to a subject with cancer a vaccinia virus lacking functions of vaccinia virus growth factor (VGF) and O1L and having a gene encoding B5R in which SCR (short consensus repeat) domains 1 to 4 have been deleted, wherein the vaccinia virus mediates oncolysis of the cancer thereby treating the cancer.
A method of treating cancer comprising intratumorally administering to a subject with cancer a vaccinia virus lacking functions of vaccinia virus growth factor (VGF) and O1L and having a gene encoding B5R in which SCR (short consensus repeat) domains 1 to 4 have been deleted, wherein the gene encoding B5R in which SCR domains 1 to 4 have been deleted comprises a signal peptide, a stalk, a transmembrane domain, and a cytoplasmic tail of B5R, and wherein said vaccinia virus mediates oncolysis of the cancer thereby treating the cancer.
Dependencies are inferred from the claim text.